Systemic therapies for metastatic renal cell carcinoma in the second-line setting: A systematic review and network meta-analysis.

ABSTRACT:

Objectives

To perform a systematic review and network meta-analysis to compare the survival benefit and safety profile of current available second-line treatment options of metastatic renal cell carcinomav.

Methods

PubMed, EMBASE, Web of Science, and Cochrane Library were systematically researched for eligible articles which were published before July 20, 2021. Studies comparing overall/progression free survival (OS/PFS), objective response rate (ORR), and/or adverse events (AEs) in patients with metastatic renal cell carcinomav were included.

Results

Nine trials (with 4911 patients) were finally included for final network meta-analysis. Cabozantinib, lenvatinib, and lenvatinib plus everolimus were associated with significantly better PFS, OS, and ORR compared with ev

SUBMITTER: Liao Y 

PROVIDER: S-EPMC9478350 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature